Dr. Narendranath Epperla, M.D.
Claim this profileOhio State University Comprehensive Cancer Center
Studies Lymphoma
Studies Non-Hodgkin's Lymphoma
6 reported clinical trials
10 drugs studied
Affiliated Hospitals
Clinical Trials Narendranath Epperla, M.D. is currently running
Acalabrutinib + Durvalumab
for Central Nervous System Lymphoma
BTK inhibition and checkpoint blockade are promising classes of therapy for central nervous system (CNS) lymphoma and have demonstrated efficacy with acceptable toxicity. A multidrug approach may carry a higher chance of durable efficacy in this aggressive disease that carries significant morbidity and mortality. Given the poor outcomes and limited options for patients who are not candidates for high-dose methotrexate, the investigators seek to evaluate the combination in this patient population. 08/30/2022: The study was originally designed for those with primary and secondary central nervous system (CNS) lymphoma. However, the first three patients who were enrolled all had secondary CNS lymphoma and most had germinal center phenotype disease with double hit phenotypes. In these three patients, two dose limiting toxicities were seen including 1 patient with grade 4 neutropenia at the time of disease progression and one with pneumonia in the setting of disease progression and worsening of existing heart disease. The third patient came off for clinical progression within cycle 1. Given the lack of response in patients with secondary CNS lymphomas, who do not exhibit the same biology as primary CNS lymphoma patients, Amendment 3 updates the study to only include patients with primary CNS lymphomas.
Recruiting1 award Phase 110 criteria
Nanochip Technology
for B-Cell Lymphoma
This trial uses a special tiny chip to monitor treatment response and detect relapse in patients with diffuse large B-cell lymphoma by checking their blood for specific genetic markers. Rituximab has been a key component in treating diffuse large B-cell lymphoma.
Recruiting1 award N/A5 criteria
More about Narendranath Epperla, M.D.
Clinical Trial Related3 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Narendranath Epperla, M.D. has experience with
- Rituximab
- Acalabrutinib
- Pemigatinib
- Pirtobrutinib
- Durvalumab
- Lenalidomide
Breakdown of trials Narendranath Epperla, M.D. has run
Lymphoma
Non-Hodgkin's Lymphoma
MALT Lymphoma
Diffuse Large B-Cell Lymphoma
Marginal Zone Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Narendranath Epperla, M.D. specialize in?
Narendranath Epperla, M.D. focuses on Lymphoma and Non-Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved treating patients, or patients who are undergoing treatment.
Is Narendranath Epperla, M.D. currently recruiting for clinical trials?
Yes, Narendranath Epperla, M.D. is currently recruiting for 3 clinical trials in Columbus Ohio. If you're interested in participating, you should apply.
Are there any treatments that Narendranath Epperla, M.D. has studied deeply?
Yes, Narendranath Epperla, M.D. has studied treatments such as Rituximab, Acalabrutinib, Pemigatinib.
What is the best way to schedule an appointment with Narendranath Epperla, M.D.?
Apply for one of the trials that Narendranath Epperla, M.D. is conducting.
What is the office address of Narendranath Epperla, M.D.?
The office of Narendranath Epperla, M.D. is located at: Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States. This is the address for their practice at the Ohio State University Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.